{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:23:36Z","timestamp":1791289416099,"version":"4.3.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["patient-research.elsevier.com","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ctrv.2013.10.003","type":"journal-article","created":{"date-parts":[[2013,10,23]],"date-time":"2013-10-23T23:03:37Z","timestamp":1382569417000},"page":"648-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities"],"prefix":"10.1016","volume":"40","author":[{"given":"Angela","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gelao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Minchella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-0636","authenticated-orcid":false,"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2013.10.003_b0005","first-page":"35","article-title":"Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients. A minimally invasive method for the detection of bladder cancer","volume":"8","author":"Utting","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0010","first-page":"241","article-title":"Les acides nucleiques du plasma sanguine chez l\u2019homme","volume":"142","author":"Mandel","year":"1940","journal-title":"CR Acad Sci Paris"},{"key":"10.1016\/j.ctrv.2013.10.003_b0015","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0020","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00404-007-0345-1","article-title":"Elevated level of cell-free plasma DNA is associated with breast cancer","volume":"276","author":"Zhong","year":"2007","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ctrv.2013.10.003_b0025","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1200\/JCO.2003.02.006","article-title":"Quantification of free circulating DNA as a diagnostic marker in lung cancer","volume":"21","author":"Sozzi","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0030","first-page":"2297","article-title":"Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer","volume":"5","author":"Chen","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0035","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00268-004-7366-8","article-title":"Molecular detection of APC, K-RAS, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers","volume":"28","author":"Wang","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.ctrv.2013.10.003_b0040","first-page":"1119","article-title":"Microsatellite alterations plasma DNA of primary breast cancer patients","volume":"6","author":"Shaw","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0045","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/1078-0432.1219.11.3","article-title":"Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer","volume":"11","author":"Fujiwara","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0050","first-page":"181","article-title":"Circulating nucleic acids (CNAs) and cancer-a survey","volume":"1775","author":"Fleischhacker","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ctrv.2013.10.003_b0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1749-6632.2000.tb06608.x","article-title":"The origin and mechanism of circulating DNA","volume":"906","author":"Stroun","year":"2000","journal-title":"Ann NY Acad Sci"},{"issue":"6","key":"10.1016\/j.ctrv.2013.10.003_b0060","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0065","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S","article-title":"Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease","volume":"51","author":"Shapiro","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0070","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2013.10.003_b0075","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1200\/JCO.2005.05.430","article-title":"Reproducibility of a semiquantitative measurement of circulating DNA in plasma from neoplastic patients","volume":"23","author":"Frattini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/1476-4598-8-105","article-title":"Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors","volume":"8","author":"Kohler","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/dna.2008.0744","article-title":"Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer","volume":"27","author":"Catarino","year":"2008","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0090","first-page":"2222","article-title":"P53mutation in plasma DNA and its prognostic value in breast cancer patients","volume":"7","author":"Shao","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0095","first-page":"67","article-title":"Soluble normal and mutated DNA sequences from single-copy genes in human blood","volume":"3","author":"Sorenson","year":"1994","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ctrv.2013.10.003_b0100","first-page":"137","article-title":"Peripheral blood mutated p53 DNA and its clinical value in human breast cancer","volume":"25","author":"Di","year":"2003","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.ctrv.2013.10.003_b0105","first-page":"3251","article-title":"Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations","volume":"59","author":"Silva","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1245\/aso.2002.9.1.71","article-title":"Persistence of tumor DNA in plasma of breast cancer patients after mastectomy","volume":"9","author":"Silva","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0115","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/gcc.20334","article-title":"Extracellular tumor DNA in plasma and overall survival in breast cancer patients","volume":"45","author":"Garcia","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10549-010-0747-9","article-title":"Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer","volume":"120","author":"Board","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl.","key":"10.1016\/j.ctrv.2013.10.003_b0125","doi-asserted-by":"crossref","first-page":"a10502","DOI":"10.1200\/jco.2010.28.15_suppl.10502","article-title":"Detection of phosphoinositide-3-kinase, catalytic, and alpha polypeptide (PIK3CA) mutations in matched tissue and plasma samples from with metastatic breast cancer","volume":"28","author":"Angenendt","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0130","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-11-2696","article-title":"Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood","volume":"18","author":"Higgins","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ctrv.2013.10.003_b0135","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.10.003_b0140","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1101\/gr.081737.108","article-title":"Active Alu retrotransposons in the human genome","volume":"18","author":"Bennett","year":"2008","journal-title":"Genome Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0145","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1196\/annals.1448.011","article-title":"Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer","volume":"1137","author":"Sunami","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ctrv.2013.10.003_b0150","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2006.05.9493","article-title":"Prediction of breast tumor progression by integrity of free circulating DNA in serum","volume":"24","author":"Umetani","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2013.10.003_b0155","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1158\/1078-0432.CCR-12-0142","article-title":"Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression","volume":"18","author":"Schwarzenbach","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0160","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1586\/erm.09.53","article-title":"DNA methylation and cancer diagnosis: new methods and applications","volume":"9","author":"Dehan","year":"2009","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.ctrv.2013.10.003_b0165","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1158\/1078-0432.CCR-04-0597","article-title":"Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients","volume":"10","author":"Dulaimi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0170","first-page":"7641","article-title":"DNA methylation in serum of breast cancer patients: an independent prognostic marker","volume":"63","author":"Muller","year":"2003","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2013.10.003_b0175","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/sj.bjc.6605013","article-title":"The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients","volume":"100","author":"Van der Auwera","year":"2009","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2013.10.003_b0180","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s13277-012-0443-y","article-title":"DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients","volume":"33","author":"Sharma","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0185","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1158\/1078-0432.CCR-07-4557","article-title":"Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer","volume":"14","author":"Fiegl","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0190","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-04-2438","article-title":"Circulating tumour specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients","volume":"65","author":"Fiegl","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0195","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1200\/JCO.2004.11.123","article-title":"Circulating deoxyribonucleic acid as a prognostic marker in non-small cell lung cancer patients undergoing chemotherapy","volume":"22","author":"Gautschi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0200","first-page":"4675","article-title":"Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients","volume":"61","author":"Sozzi","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ijc.11079","article-title":"Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer Patients","volume":"105","author":"Beau-Faller","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0210","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0304-3835(95)03742-F","article-title":"Plasma DNA as a marker of cancerous cell death: investigation in patients suffering from lung cancer and in nude mice bearing human tumour","volume":"2","author":"Fournie","year":"1995","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2013.10.003_b0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0304-3835(02)00740-1","article-title":"Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients","volume":"193","author":"Ramirez","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2013.10.003_b0220","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1196\/annals.1318.010","article-title":"Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy","volume":"1022","author":"Kimura","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2013.10.003_b0225","first-page":"3782","article-title":"P16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from nonsmall cell lung cancer","volume":"8","author":"Bearzatto","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0230","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.lungcan.2005.06.007","article-title":"Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?","volume":"50","author":"Camps","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.canlet.2007.03.008","article-title":"Origin and prognostic value of circulating KRAS mutations in lung cancer patients","volume":"254","author":"Gautschi","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2013.10.003_b0240","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2013.10.003_b0245","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/sj.bjc.6603949","article-title":"Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)","volume":"97","author":"Kimura","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0255","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/JTO.0b013e3182307f98","article-title":"Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin\/paclitaxel in non-small cell lung cancer","volume":"7","author":"Goto","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0260","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/1078-0432.CCR-08-2622","article-title":"Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients","volume":"15","author":"Young","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0265","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation","volume":"17","author":"Oxnard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0270","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1158\/1078-0432.CCR-11-1712","article-title":"Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas","volume":"17","author":"Taniguchi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0275","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1749-6632.2000.tb06594.x","article-title":"Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer","volume":"906","author":"Bruhn","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ctrv.2013.10.003_b0280","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/carcin\/bgg169","article-title":"Hypermethylation of p16INK4\u03b1 in Chinese lung cancer patients: biological and clinical implications","volume":"24","author":"Liu","year":"2003","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2013.10.003_b0285","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.1200\/JCO.2005.02.2905","article-title":"14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group","volume":"23","author":"Ramirez","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1196\/annals.1368.025","article-title":"Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool","volume":"1075","author":"Frattini","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ctrv.2013.10.003_b0295","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1196\/annals.1448.025","article-title":"Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer","volume":"1137","author":"Schwarzenbach","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"45","key":"10.1016\/j.ctrv.2013.10.003_b0300","doi-asserted-by":"crossref","first-page":"16368","DOI":"10.1073\/pnas.0507904102","article-title":"Detection and quantification of mutations in the plasma of patients with colorectal tumors","volume":"102","author":"Diehl","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2013.10.003_b0305","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.10526","article-title":"Detection of free-circulating tumor-associated DNA in serum of colorectal cancer patients and its association with prognosis","volume":"100","author":"Lecomte","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0310","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.suronc.2007.10.004","article-title":"Free circulating DNA as possible tumor marker in colorectal cancer","volume":"16","author":"Boni","year":"2007","journal-title":"Surg Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0315","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-06-1931","article-title":"Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer","volume":"12","author":"Flamini","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0320","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.10.003_b0325","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/annonc\/mdl958","article-title":"Molecular detection of TP53, KRAS and p16 promoter methylation in serum of patients with colorectal cancer and its association with prognosis. Results of a 3 years GOIM (Gruppo Oncologico dell\u2019Italia Meridionale) prospective study","volume":"17","author":"Bazan","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0330","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2013.10.003_b0335","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/172460080602100405","article-title":"Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases","volume":"21","author":"Trevisiol","year":"2006","journal-title":"Int J Biol Markers"},{"issue":"2","key":"10.1016\/j.ctrv.2013.10.003_b0340","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/SLA.0b013e3181c35c87","article-title":"Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer","volume":"251","author":"Lefebure","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2013.10.003_b0345","doi-asserted-by":"crossref","DOI":"10.1373\/clinchem.2013.206359","article-title":"Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients","author":"Taly","year":"2013","journal-title":"Clin Chem"},{"issue":"7404","key":"10.1016\/j.ctrv.2013.10.003_b0350","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2013.10.003_b0355","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1373\/clinchem.2008.115808","article-title":"Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer","volume":"55","author":"deVos","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2013.10.003_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2010.05.018","article-title":"Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer","volume":"202","author":"He","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ctrv.2013.10.003_b0365","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ijc.27505","article-title":"Prognostic role of methylated free circulating DNA in colorectal cancer","volume":"131","author":"Philipp","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0370","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1373\/clinchem.2006.068577","article-title":"Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats","volume":"52","author":"Umetani","year":"2006","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2013.10.003_b0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2003.11.023","article-title":"Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer","volume":"205","author":"Jung","year":"2004","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2013.10.003_b0380","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1078-0432.CCR-04-1237","article-title":"Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease","volume":"11","author":"Boddy","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0385","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ijc.23057","article-title":"Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators","volume":"122","author":"Ellinger","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0390","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1309\/DBPX1MFNDDJBW1FL","article-title":"Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer","volume":"129","author":"Altimari","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0395","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1158\/1078-0432.CCR-06-2781","article-title":"Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy","volume":"13","author":"Bastian","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0400","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-08-1910","article-title":"Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer","volume":"15","author":"Schwarzenbach","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bjc.2011.143","article-title":"Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis","volume":"105","author":"Wu","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0410","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1373\/clinchem.2008.108498","article-title":"Multimarker circulating DNA assay for assessing blood of prostate cancer patients","volume":"55","author":"Sunami","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2013.10.003_b0415","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1158\/1078-0432.CCR-04-2446","article-title":"Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate specific antigen recurrence following radical prostatectomy","volume":"11","author":"Bastian","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0420","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pros.20533","article-title":"Promoter hypermethylation of GSTP1, AR, and 14-3-3-sigma in serum of prostate cancer patients and its clinical relevance","volume":"67","author":"Reibenwein","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.ctrv.2013.10.003_b0425","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1158\/1078-0432.CCR-06-0130","article-title":"DNA integrity assay: a plasma-based screening tool for the detection of prostate cancer","volume":"12","author":"Hanley","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0430","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2013.10.003_b0435","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1196\/annals.1368.031","article-title":"Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR","volume":"1075","author":"Kamat","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.ctrv.2013.10.003_b0440","first-page":"3467","article-title":"Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer","volume":"32","author":"No","year":"2012","journal-title":"Anticancer Res."},{"issue":"10","key":"10.1016\/j.ctrv.2013.10.003_b0445","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4161\/cbt.5.10.3240","article-title":"Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma","volume":"5","author":"Kamat","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2013.10.003_b0450","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/cncr.24997","article-title":"Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker","volume":"116","author":"Kamat","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2013.10.003_b0455","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdq584","article-title":"Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers","volume":"22","author":"Dobrzycka","year":"2011","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2013.10.003_b0460","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.25602","article-title":"Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients","volume":"128","author":"Wimberger","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0465","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ygyno.2010.09.019","article-title":"Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors","volume":"120","author":"Liggett","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0470","doi-asserted-by":"crossref","first-page":"6476","DOI":"10.1158\/0008-5472.CAN-04-1529","article-title":"Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients","volume":"64","author":"Ibanez de Caceres","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.10.003_b0475","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1158\/1078-0432.CCR-03-0732","article-title":"The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients","volume":"10","author":"Gifford","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"3 Pt. 1","key":"10.1016\/j.ctrv.2013.10.003_b0480","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ajog.2005.01.054","article-title":"Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer","volume":"193","author":"Swisher","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ctrv.2013.10.003_b0485","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/1471-2407-12-325","article-title":"LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival","volume":"12","author":"Kuhlmann","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2013.10.003_b0490","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1158\/1078-0432.CCR-07-0853","article-title":"Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions","volume":"13","author":"Salani","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"7447","key":"10.1016\/j.ctrv.2013.10.003_b0495","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ctrv.2013.10.003_b0500","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1101\/gr.123497.111","article-title":"Genomic analysis of circulating cell-free DNA infers breast cancer dormancy","volume":"22","author":"Shaw","year":"2012","journal-title":"Genome Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213002077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213002077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T15:19:48Z","timestamp":1688570388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737213002077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0305737213002077"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.10.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}